Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs)

  • Wiernik P
  • 21

    Readers

    Mendeley users who have this article in their library.
  • 9

    Citations

    Citations of this article.

Abstract

Thalidomide and its derivatives represent a new class of antineoplastic drugs (IMiDs), which has been especially effective in certain hematologic malignancies. These agents have anti-inflammatory, antiangiogenic, and immunomodulatory properties, and target tumor cells by direct cytotoxicity and indirectly by interfering with several components of the bone marrow microenvironment. Thalidomide analogs that retain antitumor activity equal to or greater than the parent compound, but with less toxicity, have been developed. This paper summarizes what is known about the mechanisms of action of these agents, and recent clinical results. The data suggest that thalidomide analogs will play a major role in the management of certain hematologic neoplasms in the near future.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Peter H. Wiernik

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free